Cyclerion Therapeutics, Inc.

Pfizer Corporation

Amgen Inc.

Agouron Pharmaceuticals, Inc.

Sugen Incorporated

Tisento Therapeutics Inc.

Pacific Biosciences of California, Inc.

Pfizer Products Inc.

Lei Jia

Paul A Renhowe

Glen Robert Rennie

Rajesh R Iyengar

Takashi Nakai

Joon Jung

Ara Mermerian

Thomas Wai-Ho Lee

G-Yoon Jamie Im

Mitchell David Nambu

Karthik Iyer

Jingrong Jean Cui

Timothy Claude Barden

Mason Alan Pairish

Hong Shen

Pei-Pei Kung

Jerry Jialun Meng

Lee Andrew Funk

Jian Jeffrey Chen

Nuria A Tamayo

James Edward Sheppeck

Matthew Paul Bourbeau

Kexue Li

Nicholas Robert Perl

Dilip Ramakant Bhumralkar

Mark G Currie

Jennifer R Zhang

Thomas T Nguyen

Nobuko Nishimura

Qiufen May Xue

Liping H Pettus

Xiang Y Yu

Michael J Frohn

Joel D Moore

John Gordon Allen

Cathleen Elizabeth Hanau

G Davis Harris, Jr

Colleen Hudson

Xiaoyuan Li

Michelle Bich Tran-Dube

Abhisek Banerjee

Kim Tang

Peter Germano

Iriny Botrous

Kimberly Kafadar Long

Fang-Jie Zhang

George Todd Milne

Stephen A Kolodziej

Ji Yu Chu

Joanne Johnson

Xiaoyuan (Sharon) Li

Jason (Qishen) Lin

Christopher G Nelson

Allison Walter

Stephen Wilson Turner

Jonas Korlach

Qingyian Liu

Robert Steven Kania

Jeremiah Hanes

Cynthia Louise Palmer

Matthew R Kaller

Kevin Travers

John Lyle

Michael D Varney

Ana Elena Minatti

Hengmiao Cheng

Jonathan Dante Low

Steven Lee Bender

Vu Van Ma

Jon M Sorenson

Benjamin A Flusberg

James A Brown

Michael Raymond Collins

Judith Gail Deal

Dale R Webster

Mary Catherine Johnson

Phuong Thi Quy Le

G Davis Harris

Jacqui Elizabeth Hoffman

Jessica Lee

Joseph Puglisi

Zhengwei Peng

Mary Catherine Walton Cabrera

Michelle Bich Tran-Dubé

Stephen James Cripps

Dilip Bhumralkar

Jason(qishen) Lin

Xiaoyuan(sharon) Li

Paul Allan Renhowe

Jingjong Jean Cui

Jason Lin

G Davis Harris Jr

Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

KIF18A inhibitors

The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula I:

sGC stimulators

Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I). 

SGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: 

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, J, n, J, J, X, Z, Z, R, R, Y, R, o and W are as defined herein.

Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors

Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET. 

Aminoheteroaryl compounds as protein kinase inhibitors

The invention relates to compounds of the formula I or a pharmaceutically acceptable salt thereof, wherein R, R, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

Triazolopyrazine derivatives

Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET 

Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Growing community of inventors

San Diego, CA, United States of America

Lei Jia